Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE

Brain iron elevation is implicated in Alzheimer's disease (AD) pathogenesis, but the impact of iron on disease outcomes has not been previously explored in a longitudinal study. Ferritin is the major iron storage protein of the body; by using cerebrospinal fluid (CSF) levels of ferritin as an index, we explored whether brain iron status impacts longitudinal outcomes in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. We show that baseline CSF ferritin levels were negatively associated with cognitive performance over 7 years in 91 cognitively normal, 144 mild cognitive impairment (MCI) and 67 AD subjects, and predicted MCI conversion to AD. Ferritin was strongly associated with CSF apolipoprotein E levels and was elevated by the Alzheimer's risk allele, APOE-ɛ4. These findings reveal that elevated brain iron adversely impacts on AD progression, and introduce brain iron elevation as a possible mechanism for APOE-ɛ4 being the major genetic risk factor for AD.

[1]  H. Zetterberg,et al.  Hyperphosphorylation of tau protein in superficial CNS siderosis , 2008, Journal of the Neurological Sciences.

[2]  M. Weiner,et al.  CSF Apo-E levels associate with cognitive decline and MRI changes , 2014, Acta Neuropathologica.

[3]  Blaine R. Roberts,et al.  Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export , 2012, Nature Medicine.

[4]  Chengjie Xiong,et al.  Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis , 2011, PloS one.

[5]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[6]  T. Jacques,et al.  Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity. , 2007, Archives of neurology.

[7]  Achim Zeileis,et al.  Extended Beta Regression in R: Shaken, Stirred, Mixed, and Partitioned , 2012 .

[8]  J. Connor,et al.  Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome , 2000, Neurology.

[9]  Nick C Fox,et al.  Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals , 2014, Translational Psychiatry.

[10]  K. Jellinger,et al.  Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[11]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[12]  P. Scheltens,et al.  Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy , 1994, Journal of Neural Transmission - Parkinsons Disease and Dementia Section.

[13]  A. Fagan,et al.  Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. , 2012, Human molecular genetics.

[14]  D. Agard,et al.  Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. , 1994 .

[15]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[16]  W. M. van der Flier,et al.  CSF biomarkers predict rate of cognitive decline in Alzheimer disease , 2009, Neurology.

[17]  Y. O. Kim,et al.  Diagnostic capability of CSF ferritin in children with meningitis. , 2003, Pediatric neurology.

[18]  Philip S. Insel,et al.  Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults , 2014, Neurobiology of Aging.

[19]  R. Palmiter,et al.  Apolipoprotein E ablation decreases synaptic vesicular zinc in the brain , 2010, BioMetals.

[20]  James R. Connor,et al.  HFE gene variants, iron, and lipids: a novel connection in Alzheimer’s disease , 2014, Front. Pharmacol..

[21]  Xudong Huang,et al.  The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. , 1999, Biochemistry.

[22]  D. McLachlan,et al.  Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.

[23]  Julien Milles,et al.  7T T2 ∗-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease , 2015, Neurobiology of Aging.

[24]  T. Schneider-Axmann,et al.  Accumulation of intraneuronal Aβ correlates with ApoE4 genotype , 2010, Acta Neuropathologica.

[25]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[26]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[27]  G. Bartzokis,et al.  Brain Ferritin Iron as a Risk Factor for Age at Onset in Neurodegenerative Diseases , 2004 .

[28]  C. Quintana,et al.  Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. , 2006, Journal of structural biology.

[29]  J. Kulisevsky,et al.  Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging , 2003, International journal of geriatric psychiatry.

[30]  Robert A. Dean,et al.  Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI , 2011, Acta Neuropathologica.

[31]  Xuesheng Zhang,et al.  Cellular iron status influences the functional relationship between microglia and oligodendrocytes , 2006, Glia.

[32]  Ö. Melefors,et al.  Secretion of Ferritin by Iron-laden Macrophages and Influence of Lipoproteins , 2004, Free radical research.

[33]  J. Connor,et al.  A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.

[34]  T. Moos,et al.  Expression of ferritin protein and subunit mRNAs in normal and iron deficient rat brain. , 1999, Brain research. Molecular brain research.

[35]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[36]  J. Connor,et al.  The lipophilic iron compound TMH-ferrocene [(3,5,5-trimethylhexanoyl)ferrocene] increases iron concentrations, neuronal l-ferritin, and heme oxygenase in brains of BALB/c mice , 2002, Biological Trace Element Research.

[37]  Ian Fellows,et al.  Deducer: A Data Analysis GUI for R , 2012 .

[38]  Amity E. Green,et al.  3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects , 2010, Neurobiology of Aging.

[39]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[40]  Hironobu Naiki,et al.  Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. , 2002, Journal of neurochemistry.

[41]  D. Michaelson,et al.  Increased levels of intracellular iron in the brains of ApoE-deficient mice with closed head injury. , 2000, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[42]  C. Masters,et al.  Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease , 2010, Cell.

[43]  E. Diamandis,et al.  Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls , 2014, Acta Neuropathologica.

[44]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Philip S. Insel,et al.  CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders , 2013, Translational Psychiatry.

[46]  DuhamelAlain,et al.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease. , 2014 .